AZ-话题@MedSci

#AZ#

260篇内容 | 4525人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714727, encodeId=72331e1472752, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=武田联手Frazier4100万美元打造泌尿学新公司, objectType=article, longId=65150, objectId=f3a76515099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3a76515099, replyNumber=0, likeNumber=67, createdTime=2016-11-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3a76515099, moduleTitle=武田联手Frazier4100万美元打造泌尿学新公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3a76515099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714726, encodeId=17a31e1472673, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet：对于侵袭性真菌病，Isavuconazole不劣于伏立康唑, objectType=article, longId=60551, objectId=54a46055108, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54a46055108, replyNumber=0, likeNumber=73, createdTime=2016-10-14, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54a46055108, moduleTitle=Lancet：对于侵袭性真菌病，Isavuconazole不劣于伏立康唑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54a46055108)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714730, encodeId=dca81e147304a, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=2016国际肝病会议：治疗基因型1型和4型HCV感染，Elbasvir/grazoprevir方案的安全性和疗效性更优, objectType=article, longId=66791, objectId=ff0366e9153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0366e9153, replyNumber=0, likeNumber=85, createdTime=2017-02-02, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0366e9153, moduleTitle=2016国际肝病会议：治疗基因型1型和4型HCV感染，Elbasvir/grazoprevir方案的安全性和疗效性更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0366e9153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714721, encodeId=99661e1472108, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AIM：Grazoprevir和Elbasvir的新组合方案为HCV感染者提供了新的治疗选择, objectType=article, longId=53210, objectId=e67d53210e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67d53210e4, replyNumber=0, likeNumber=60, createdTime=2016-02-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67d53210e4, moduleTitle=AIM：Grazoprevir和Elbasvir的新组合方案为HCV感染者提供了新的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67d53210e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714720, encodeId=300b1e1472029, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet HIV：Grazoprevir加Elbasvir可有效治疗HIV和HCV共感染的患者, objectType=article, longId=53180, objectId=16e6531804a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e6531804a, replyNumber=0, likeNumber=66, createdTime=2016-02-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e6531804a, moduleTitle=Lancet HIV：Grazoprevir加Elbasvir可有效治疗HIV和HCV共感染的患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16e6531804a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714724, encodeId=a7571e14724c8, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准Ninlaro（ixazomib）用于治疗多发性骨髓瘤（MM），今年共批准三个MM新药, objectType=article, longId=59251, objectId=128c5925127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=128c5925127, replyNumber=0, likeNumber=64, createdTime=2016-05-22, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=128c5925127, moduleTitle=FDA批准Ninlaro（ixazomib）用于治疗多发性骨髓瘤（MM），今年共批准三个MM新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=128c5925127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714723, encodeId=8b6b1e147235a, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet：4-5期慢性肾病患者感染HCV治疗：grazoprevir和elbasvir效果良好, objectType=article, longId=57067, objectId=fde15e0670c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde15e0670c, replyNumber=0, likeNumber=59, createdTime=2016-07-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde15e0670c, moduleTitle=Lancet：4-5期慢性肾病患者感染HCV治疗：grazoprevir和elbasvir效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde15e0670c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714715, encodeId=ca6d1e1471556, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=决默沙东Zerbaxa，阿特维斯新型产品Avycaz喜获FDA批准, objectType=article, longId=47531, objectId=9c354e5311d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c354e5311d, replyNumber=0, likeNumber=84, createdTime=2015-10-24, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c354e5311d, moduleTitle=决默沙东Zerbaxa，阿特维斯新型产品Avycaz喜获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c354e5311d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714718, encodeId=fd471e14718cc, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效, objectType=article, longId=51444, objectId=091f5144489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091f5144489, replyNumber=0, likeNumber=97, createdTime=2015-08-03, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091f5144489, moduleTitle=N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091f5144489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714717, encodeId=b3e21e1471786, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AIM：Grazoprevir-Elbasvir联合对慢性丙肝（HCV）治疗抵抗患者有显著效果, objectType=article, longId=49877, objectId=9697498e729, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9697498e729, replyNumber=0, likeNumber=96, createdTime=2015-09-29, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9697498e729, moduleTitle=AIM：Grazoprevir-Elbasvir联合对慢性丙肝（HCV）治疗抵抗患者有显著效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9697498e729)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714712, encodeId=dbcc1e14712f5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=ASH 2014：ixazomib单药维持可扩大多发性骨髓瘤缓解深度, objectType=article, longId=44371, objectId=05e8443e1ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05e8443e1ea, replyNumber=0, likeNumber=97, createdTime=2015-07-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05e8443e1ea, moduleTitle=ASH 2014：ixazomib单药维持可扩大多发性骨髓瘤缓解深度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05e8443e1ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714719, encodeId=53d31e14719e5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Teva迟发型运动障碍药Deutetrabenazine临床结果可喜，系该领域首例疗法, objectType=article, longId=52401, objectId=2e3152401d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e3152401d2, replyNumber=0, likeNumber=83, createdTime=2015-12-12, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e3152401d2, moduleTitle=Teva迟发型运动障碍药Deutetrabenazine临床结果可喜，系该领域首例疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e3152401d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714711, encodeId=5c231e14711a5, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=ASH 2014：武田ixazomib单药维持疗法有效改善多发性骨髓瘤（MM）缓解深度, objectType=article, longId=43835, objectId=55fa43835bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55fa43835bc, replyNumber=0, likeNumber=61, createdTime=2015-08-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55fa43835bc, moduleTitle=ASH 2014：武田ixazomib单药维持疗法有效改善多发性骨髓瘤（MM）缓解深度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55fa43835bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714716, encodeId=cd6c1e147163d, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Pharmazie：抗痛风药用植物的详细审查, objectType=article, longId=48469, objectId=506948469ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=506948469ce, replyNumber=0, likeNumber=69, createdTime=2016-02-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=506948469ce, moduleTitle=Pharmazie：抗痛风药用植物的详细审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=506948469ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714714, encodeId=167b1e147145f, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗, objectType=article, longId=47374, objectId=d6104e37469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6104e37469, replyNumber=0, likeNumber=78, createdTime=2015-11-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6104e37469, moduleTitle=JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6104e37469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714713, encodeId=fca11e14713a6, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效, objectType=article, longId=47035, objectId=ed9e4e0358a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed9e4e0358a, replyNumber=0, likeNumber=70, createdTime=2015-03-26, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed9e4e0358a, moduleTitle=武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed9e4e0358a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714708, encodeId=c1351e1470867, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib, objectType=article, longId=42889, objectId=dba242889af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dba242889af, replyNumber=0, likeNumber=62, createdTime=2015-03-10, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dba242889af, moduleTitle=Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dba242889af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714707, encodeId=37e71e14707a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=阿斯利康新抗生素药物CAZ-AVI治疗并发性腹腔内感染临床三期研究获得圆满成功, objectType=article, longId=39494, objectId=c199394940f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c199394940f, replyNumber=0, likeNumber=74, createdTime=2015-01-10, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c199394940f, moduleTitle=阿斯利康新抗生素药物CAZ-AVI治疗并发性腹腔内感染临床三期研究获得圆满成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c199394940f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714709, encodeId=f75f1e14709e7, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=失而复得，罗氏白血病药物Gazyvaro重获NICE批准, objectType=article, longId=43573, objectId=74ac435e3f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ac435e3f6, replyNumber=0, likeNumber=59, createdTime=2015-04-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ac435e3f6, moduleTitle=失而复得，罗氏白血病药物Gazyvaro重获NICE批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ac435e3f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714710, encodeId=c87e1e14710cd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=阿特维斯新型抗生素ceftazidime-avibactam有望获FDA批准, objectType=article, longId=43721, objectId=486c43e21cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486c43e21cd, replyNumber=0, likeNumber=72, createdTime=2015-10-16, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486c43e21cd, moduleTitle=阿特维斯新型抗生素ceftazidime-avibactam有望获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486c43e21cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

武田联手Frazier4100万美元打造泌尿学新公司

2016-11-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet：对于侵袭性真菌病，Isavuconazole不劣于伏立康唑

2016-10-14

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

2016国际肝病会议：治疗基因型1型和4型HCV感染，Elbasvir/grazoprevir方案的安全性和疗效性更优

2017-02-02

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AIM：Grazoprevir和Elbasvir的新组合方案为HCV感染者提供了新的治疗选择

2016-02-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet HIV：Grazoprevir加Elbasvir可有效治疗HIV和HCV共感染的患者

2016-02-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准Ninlaro（ixazomib）用于治疗多发性骨髓瘤（MM），今年共批准三个MM新药

2016-05-22

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet：4-5期慢性肾病患者感染HCV治疗：grazoprevir和elbasvir效果良好

2016-07-13

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

决默沙东Zerbaxa，阿特维斯新型产品Avycaz喜获FDA批准

2015-10-24

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

N Engl J Med.：AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效

2015-08-03

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AIM：Grazoprevir-Elbasvir联合对慢性丙肝（HCV）治疗抵抗患者有显著效果

2015-09-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

ASH 2014：ixazomib单药维持可扩大多发性骨髓瘤缓解深度

2015-07-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Teva迟发型运动障碍药Deutetrabenazine临床结果可喜，系该领域首例疗法

2015-12-12

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

ASH 2014：武田ixazomib单药维持疗法有效改善多发性骨髓瘤（MM）缓解深度

2015-08-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Pharmazie：抗痛风药用植物的详细审查

2016-02-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗

2015-11-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效

2015-03-26

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib

2015-03-10

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

阿斯利康新抗生素药物CAZ-AVI治疗并发性腹腔内感染临床三期研究获得圆满成功

2015-01-10

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

失而复得，罗氏白血病药物Gazyvaro重获NICE批准

2015-04-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

阿特维斯新型抗生素ceftazidime-avibactam有望获FDA批准

2015-10-16

科室
- - 订阅+
  - 更多科室
工具
服务